Abstract | OBJECTIVE: DATA SOURCES: Literature was accessed through PubMed (1948-December 2009). Pitavastatin, itavastatin, nisvastatin, NK 104, and NKS 104 were used as search terms. Results were limited to articles written in the English language. STUDY SELECTION AND DATA EXTRACTION: All articles identified from the data source were reviewed for inclusion. Articles included were those pertaining to the pharmacology and pharmacokinetic properties of pitavastatin, in addition to original research evaluating the clinical efficacy of pitavastatin for hypercholesterolemia. DATA SYNTHESIS: CONCLUSIONS: In light of the lack of outcome data, pitavastatin offers no clear advantage over other drugs in this class.
|
Authors | Terri M Wensel, Bruce A Waldrop, Brian Wensel |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 44
Issue 3
Pg. 507-14
(Mar 2010)
ISSN: 1542-6270 [Electronic] United States |
PMID | 20179258
(Publication Type: Comparative Study, Journal Article, Review)
|
Chemical References |
- Cholesterol, LDL
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Quinolines
- pitavastatin
|
Topics |
- Cholesterol, LDL
(blood, drug effects)
- Drug Interactions
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(adverse effects, pharmacokinetics, therapeutic use)
- Hypercholesterolemia
(drug therapy, physiopathology)
- Quinolines
(adverse effects, pharmacokinetics, therapeutic use)
- Randomized Controlled Trials as Topic
|